It will mean more medicines receive approval for use on the NHS in England at the same time as they are licensed for use in the UK. It’s anticipated that patients in England will receive the newest ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality ...

This update to the NICE HealthTech programme manual sets out in greater detail methods to be used by the NICE HealthTech programme when developing HealthTech guidance. This includes approaches for ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

Evaluation committee members The highly specialised technologies (HST) committee is a standing advisory committee of NICE. This topic was considered as a cost comparison evaluation by the lead team of ...

Vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) is available on the NHS as a possible treatment for cystic fibrosis. It is for people 6 years and over who have at least 1 F508del mutation in the ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

5 Minimum evidence standards There is some clinical evidence that suggests that the digital front door technologies support the pre-assessment process for accessing Talking Therapies services, and ...

NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because the company did not ...